Manfred Danilovits
- Cost and cost-effectiveness of multidrug-resistant tuberculosis treatment in Estonia and RussiaBy Katherine Floyd, Raymond Hutubessy, Kai Kliiman, Rosella Centis, Nina Khurieva, Wieslaw Jakobowiak, Manfred Danilovits, Genadi Peremitin, Salmaan Keshavjee and Giovanni Battista MiglioriKatherine FloydRaymond HutubessyKai KliimanRosella CentisNina KhurievaWieslaw JakobowiakManfred DanilovitsGenadi PeremitinSalmaan KeshavjeeGiovanni Battista Migliori
- Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosisBy Vija Skripconoka, Manfred Danilovits, Lea Pehme, Tarmo Tomson, Girts Skenders, Tiina Kummik, Andra Cirule, Vaira Leimane, Anu Kurve, Klavdia Levina, Lawrence J. Geiter, Davide Manissero and Charles D. WellsVija Skripconoka*Riga East University Hospital, Centre of Tuberculosis and Lung Diseases, Riga, LatviaManfred Danilovits#Tartu University Clinics, Lung Hospital, TartuLea Pehme#Tartu University Clinics, Lung Hospital, TartuTarmo Tomson¶North Estonian Medical Centre Foundation, Centre of Pulmonology, Tallinn, EstoniaGirts Skenders*Riga East University Hospital, Centre of Tuberculosis and Lung Diseases, Riga, LatviaTiina Kummik#Tartu University Clinics, Lung Hospital, TartuAndra Cirule*Riga East University Hospital, Centre of Tuberculosis and Lung Diseases, Riga, LatviaVaira Leimane*Riga East University Hospital, Centre of Tuberculosis and Lung Diseases, Riga, LatviaAnu Kurve¶North Estonian Medical Centre Foundation, Centre of Pulmonology, Tallinn, EstoniaKlavdia Levina¶North Estonian Medical Centre Foundation, Centre of Pulmonology, Tallinn, EstoniaLawrence J. Geiter+Otsuka Pharmaceutical Development and Commercialization, Rockville, MD, USADavide Manissero§Otsuka SA, Geneva, SwitzerlandCharles D. Wells+Otsuka Pharmaceutical Development and Commercialization, Rockville, MD, USA
- Delamanid Improves Outcomes and Reduces Mortality for Multidrug-Resistant TuberculosisBy Vija Skripconoka, Manfred Danilovits, Lea Pehme, Tarmo Tomson, Girts Skenders, Tiina Kummik, Andra Cirule, Vaira Leimane, Anu Kurve, Klavdia Levina, Lawrence J. Geiter, Davide Manissero and Charles D. WellsArticle | Published in 2012 in European Respiratory JournalVija Skripconoka*Riga East University Hospital – Centre of Tuberculosis and Lung Diseases, LatviaManfred Danilovits#Tartu University Clinics, Lung Hospital, EstoniaLea Pehme#Tartu University Clinics, Lung Hospital, EstoniaTarmo Tomson¶North Estonian Medical Centre Foundation, Centre of Pulmonology, Tallinn, EstoniaGirts Skenders*Riga East University Hospital – Centre of Tuberculosis and Lung Diseases, LatviaTiina Kummik#Tartu University Clinics, Lung Hospital, EstoniaAndra Cirule*Riga East University Hospital – Centre of Tuberculosis and Lung Diseases, LatviaVaira Leimane*Riga East University Hospital – Centre of Tuberculosis and Lung Diseases, LatviaAnu Kurve¶North Estonian Medical Centre Foundation, Centre of Pulmonology, Tallinn, EstoniaKlavdia Levina¶North Estonian Medical Centre Foundation, Centre of Pulmonology, Tallinn, EstoniaLawrence J. Geiter+Otsuka Pharmaceutical Development and Commercialization, Rockville, MD, USADavide Manissero§Otsuka SA, Geneva, SwitzerlandCharles D. Wells+Otsuka Pharmaceutical Development and Commercialization, Rockville, MD, USA
- Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosisBy Alexander S. Pym, Andreas H. Diacon, Shen-Jie Tang, Francesca Conradie, Manfred Danilovits, Charoen Chuchottaworn, Irina Vasilyeva, Koen Andries, Nyasha Bakare, Tine De Marez, Myriam Haxaire-Theeuwes, Nacer Lounis, Paul Meyvisch, Ben Van Baelen, Rolf P.G. van Heeswijk and Brian DannemannArticle | Published in 2015 in European Respiratory JournalAlexander S. Pym1Medical Research Council and Kwazulu Research Institute for TB and HIV (K-RITH), Durban, South AfricaAndreas H. Diacon2Division of Medical Physiology and Dept of Science and Technology/National Research Foundation Centre of Excellence for Biomedical Tuberculosis Research and Medical Research Council Centre for Tuberculosis Research, Faculty of Medicine and Health Sciences, University of Stellenbosch, Cape Town, South AfricaShen-Jie Tang3Tuberculosis Dept, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumour Research Institute, Beijing, ChinaFrancesca Conradie4Clinical HIV Research Unit, Dept of Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South AfricaManfred Danilovits5Tartu University Lung Hospital, Tartu, EstoniaCharoen Chuchottaworn6Chest Disease Institute, Ministry of Public Health, Nonthaburi, ThailandIrina Vasilyeva7Central Tuberculosis Research Institute, Russian Academy of Medical Sciences, Moscow, RussiaKoen Andries8Janssen Infectious Diseases BVBA, Beerse, BelgiumNyasha Bakare9Janssen Research & Development LLC, Titusville, NJ, USATine De Marez9Janssen Research & Development LLC, Titusville, NJ, USAMyriam Haxaire-Theeuwes8Janssen Infectious Diseases BVBA, Beerse, BelgiumNacer Lounis8Janssen Infectious Diseases BVBA, Beerse, BelgiumPaul Meyvisch8Janssen Infectious Diseases BVBA, Beerse, BelgiumBen Van Baelen8Janssen Infectious Diseases BVBA, Beerse, BelgiumRolf P.G. van Heeswijk8Janssen Infectious Diseases BVBA, Beerse, BelgiumBrian Dannemann9Janssen Research & Development LLC, Titusville, NJ, USA
- Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosisBy Alexander S. Pym, Andreas H. Diacon, Shen-Jie Tang, Francesca Conradie, Manfred Danilovits, Charoen Chuchottaworn, Irina Vasilyeva, Koen Andries, Nyasha Bakare, Tine De Marez, Myriam Haxaire-Theeuwes, Nacer Lounis, Paul Meyvisch, Ben Van Baelen, Rolf P.G. van Heeswijk and Brian DannemannAlexander S. Pym1Medical Research Council and Kwazulu Research Institute for TB and HIV (K-RITH), Durban, South AfricaAndreas H. Diacon2Division of Medical Physiology and Dept of Science and Technology/National Research Foundation Centre of Excellence for Biomedical Tuberculosis Research and Medical Research Council Centre for Tuberculosis Research, Faculty of Medicine and Health Sciences, University of Stellenbosch, Cape Town, South AfricaShen-Jie Tang3Tuberculosis Dept, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumour Research Institute, Beijing, ChinaFrancesca Conradie4Clinical HIV Research Unit, Dept of Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South AfricaManfred Danilovits5Tartu University Lung Hospital, Tartu, EstoniaCharoen Chuchottaworn6Chest Disease Institute, Ministry of Public Health, Nonthaburi, ThailandIrina Vasilyeva7Central Tuberculosis Research Institute, Russian Academy of Medical Sciences, Moscow, RussiaKoen Andries8Janssen Infectious Diseases BVBA, Beerse, BelgiumNyasha Bakare9Janssen Research & Development LLC, Titusville, NJ, USATine De Marez9Janssen Research & Development LLC, Titusville, NJ, USAMyriam Haxaire-Theeuwes8Janssen Infectious Diseases BVBA, Beerse, BelgiumNacer Lounis8Janssen Infectious Diseases BVBA, Beerse, BelgiumPaul Meyvisch8Janssen Infectious Diseases BVBA, Beerse, BelgiumBen Van Baelen8Janssen Infectious Diseases BVBA, Beerse, BelgiumRolf P.G. van Heeswijk8Janssen Infectious Diseases BVBA, Beerse, BelgiumBrian Dannemann9Janssen Research & Development LLC, Titusville, NJ, USA
Buying books on this site
Purchases made on this website are of electronic books only.
About the ERS books
The ERS Monograph is the quarterly book series from the European Respiratory Society. Each Monograph covers a specific area of respiratory medicine, providing in-depth reviews that give clinicians at all levels a concise, comprehensive guide to symptoms, diagnosis and treatment.
The ERS Handbooks are compact guides to broad areas of the respiratory field. Launched in 2010, the series now covers adult, paediatric and sleep respiratory medicine, includes a companion volume of self-assessment questions and features the ERS Practical Handbooks.
